|Day Low/High||141.02 / 143.92|
|52 Wk Low/High||63.48 / 95.55|
Idexx Laboratories beat on earnings per share and revenue expectations, but the trend is still good, Cramer said.
Cramer shares his views on the pajama traders, and talks turkey about pet stocks.
Cramer can't understand why shares of Johnson Controls spinoff Adient aren't trading higher.
Going into earnings what the market needs now is more negativity, Cramer says.
The Mars-VCA deal is yet another sign that pet health is a robust business.
Mars is making moves in 'one of the fastest growing secular stories in the world' with its acquisition of VCA, TheStreet's Jim Cramer said.
Jim Cramer says the deal between Mars and VCA is another example of how pet pampering is becoming big business.
From data storage and oil markets to the 'humanization of pets,' these stocks are worth a closer look.
Jim Cramer says stocks keep leapfrogging their peers in sectors like airlines and semiconductors.
Bank of America is a buy, Jim Cramer says. And Morgan Stanley is also cheap.
Jim Cramer says buyers just can't wait for this market to come down.
Jim Cramer says Freshpet is only a takeover play and suggests buying Zoetis or Idexx Labs instead.
MGM: 'I like the CEO and I like the REIT,' Jim Cramer says.
Know which stocks are interest-rate sensitive and which don't care, says Jim Cramer.
The animal health industry looks poised for growth, analysts say, and Idexx Laboratories IDXX stands to benefit.
Cramer is sticking with International Paper and likes Advanced Micro Devices.
This is not the time to sell in a panic, Cramer says.
These stocks have both short-term gain catalysts and longer-term growth potential.